Disclosure-driven uncertainty in China’s antibody drug patent examination: enablement, support and a roadmap for foreign applicants
Journal of Intellectual Property Law & Practice · 24.10.2026 · 21 (10) · 690-702
DOI: 10.1093/jiplp/jpag055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Intellectual Property Law & Practice, online erschienen am 29.05.2026. Verfasst von Shi Chen und 1 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
This article examines disclosure-driven uncertainty in China’s examination of antibody drug patents and asks how foreign applicants can secure protection under the China National IP Administration’s practice. China has become a key jurisdiction for antibody drug innovation and first approvals. Yet, its patent disclosure regime remains largely calibrated to chemical drugs, giving rise to unpredictability in the enablement and claim-support review. We combine doctrinal analysis of the Chinese Patent Law and the Chinese Guidelines for Patent Examination with practice-based review of prosecution dynamics to identify key frictions and develop a clear prosecution roadmap. We find that (i) enablement standards lack stable operational guidance, (ii) claim-support review is comparatively stringent, especially for functionally based claiming and (iii) disclosure defects are sometimes folded into inventive-step analysis. Practically, applicants should front-load robust experimental evidence, build a tiered claim architecture, respond to office actions with a diagnosis and rebuttal structure, avoid cross-references by strengthening written documentation, and use incorporation by reference mechanisms to cure filing-stage omissions where eligible.
Zitieren
APA
Chen, S., & Hou, Y. (2026). Disclosure-driven uncertainty in China’s antibody drug patent examination: enablement, support and a roadmap for foreign applicants. Journal of Intellectual Property Law & Practice, 21(10), 690-702. https://doi.org/10.1093/jiplp/jpag055
Vancouver
Chen S, Hou Y. Disclosure-driven uncertainty in China’s antibody drug patent examination: enablement, support and a roadmap for foreign applicants. Journal of Intellectual Property Law & Practice. 2026;21(10):690-702. doi:10.1093/jiplp/jpag055
BibTeX
@article{Chen2026,
author = {Chen, Shi and Hou, Yanqiu},
title = {Disclosure-driven uncertainty in China’s antibody drug patent examination: enablement, support and a roadmap for foreign applicants},
journal = {Journal of Intellectual Property Law & Practice},
year = {2026},
volume = {21},
number = {10},
pages = {690--702},
doi = {10.1093/jiplp/jpag055}
}
EUVIMED